HRT Financial LLC Sells 568 Shares of Abbott Laboratories (ABT)

HRT Financial LLC decreased its stake in shares of Abbott Laboratories (NYSE:ABT) by 16.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 2,818 shares of the healthcare product maker’s stock after selling 568 shares during the period. HRT Financial LLC’s holdings in Abbott Laboratories were worth $203,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of ABT. Pinkerton Retirement Specialists LLC raised its holdings in shares of Abbott Laboratories by 0.3% in the 4th quarter. Pinkerton Retirement Specialists LLC now owns 49,500 shares of the healthcare product maker’s stock valued at $3,580,000 after acquiring an additional 147 shares in the last quarter. Delta Asset Management LLC TN raised its holdings in shares of Abbott Laboratories by 1.3% in the 4th quarter. Delta Asset Management LLC TN now owns 11,614 shares of the healthcare product maker’s stock valued at $840,000 after acquiring an additional 150 shares in the last quarter. Annex Advisory Services LLC raised its holdings in shares of Abbott Laboratories by 1.0% in the 4th quarter. Annex Advisory Services LLC now owns 15,089 shares of the healthcare product maker’s stock valued at $1,091,000 after acquiring an additional 150 shares in the last quarter. Fairview Capital Investment Management LLC raised its holdings in shares of Abbott Laboratories by 2.5% in the 4th quarter. Fairview Capital Investment Management LLC now owns 6,168 shares of the healthcare product maker’s stock valued at $446,000 after acquiring an additional 151 shares in the last quarter. Finally, Tuttle Tactical Management raised its holdings in shares of Abbott Laboratories by 1.5% in the 4th quarter. Tuttle Tactical Management now owns 10,353 shares of the healthcare product maker’s stock valued at $749,000 after acquiring an additional 153 shares in the last quarter. 75.20% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE ABT opened at $76.75 on Thursday. The stock has a market cap of $133.67 billion, a P/E ratio of 26.65, a PEG ratio of 1.97 and a beta of 1.13. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.20 and a current ratio of 1.62. Abbott Laboratories has a 1-year low of $56.81 and a 1-year high of $80.74.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.63 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.02. The company had revenue of $7.54 billion for the quarter, compared to analysts’ expectations of $7.49 billion. Abbott Laboratories had a return on equity of 16.91% and a net margin of 8.53%. Abbott Laboratories’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same period last year, the firm posted $0.59 EPS. As a group, equities analysts expect that Abbott Laboratories will post 3.21 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be issued a dividend of $0.32 per share. The ex-dividend date is Friday, April 12th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.67%. Abbott Laboratories’s dividend payout ratio is 44.44%.

In related news, insider Jaime Contreras sold 177,457 shares of the firm’s stock in a transaction that occurred on Wednesday, January 30th. The stock was sold at an average price of $70.00, for a total transaction of $12,421,990.00. Following the transaction, the insider now directly owns 100,985 shares in the company, valued at approximately $7,068,950. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Brian B. Yoor sold 2,246 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $78.00, for a total value of $175,188.00. Following the transaction, the chief financial officer now owns 116,627 shares in the company, valued at $9,096,906. The disclosure for this sale can be found here. Over the last three months, insiders have sold 336,939 shares of company stock worth $24,808,980. 0.70% of the stock is currently owned by insiders.

Several analysts have weighed in on ABT shares. Citigroup cut Abbott Laboratories from a “neutral” rating to a “sell” rating and lowered their price target for the company from $72.00 to $68.00 in a report on Wednesday, January 2nd. Zacks Investment Research cut Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, March 5th. Bank of America reaffirmed a “buy” rating and issued a $81.00 price target (up previously from $73.00) on shares of Abbott Laboratories in a report on Thursday, February 7th. Wells Fargo & Co reissued a “buy” rating on shares of Abbott Laboratories in a report on Thursday, March 14th. Finally, Morgan Stanley raised their price objective on Abbott Laboratories from $82.00 to $85.00 and gave the company an “overweight” rating in a report on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $80.48.

ILLEGAL ACTIVITY NOTICE: This article was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.com-unik.info/2019/04/25/hrt-financial-llc-sells-568-shares-of-abbott-laboratories-abt.html.

Abbott Laboratories Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Read More: Moving Average (MA)

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit